类风湿关节炎的遗传学
本文综述了类风湿关节炎(RA)的遗传学基础,指出RA是一种多基因疾病,遗传率约60%。文章总结了迄今与RA易感性相关的最显著遗传变异,重点关注HLA II类基因在不同种族中的贡献,并讨论了药物基因组学在RA管理中的潜在应用。
要点
- RA遗传率约60%,为多基因疾病。
- HLA II类基因是RA易感性的重要遗传因素。
- 药物基因组学有望指导RA治疗策略。
核心结论
- RA是一种多基因疾病,具有显著的遗传成分,遗传率估计为60%。
研究设计与样本
- 本文为综述,总结了大规模全基因组关联研究(GWAS)和荟萃分析揭示的RA相关常见变异。
主要发现
- 大规模GWAS和荟萃分析揭示了人群中常见的疾病相关变异,可能累积贡献于RA发病。
关键数值与推荐
- RA患者平均预期寿命缩短3-10年。
- RA遗传率估计为60%。
临床怎么用
- 通过识别与治疗反应或毒性相关的多态性,药物基因组学可能应用于RA管理。
- 利用遗传变异指导治疗策略可能降低英国国家医疗服务体系(NHS)成本并大幅改善患者体验和生活质量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RA is a chronic systemic inflammatory disease that primarily affects the small joints of the hands and feet, and results in a mean reduction in life expectancy of 3-10 years. RA is a multigene disorder with a substantial genetic component and a heritability estimate of 60%. Large-scale Genome-Wide Association Studies (GWAS) and meta-analyses have revealed common disease-associated variants in the population that may contribute cumulatively to RA pathogenesis. This review identifies the most significant genetic variants associated with RA susceptibility to date, with particular focus on the contribution of the HLA class II genes across different ethnic groups. Also discussed are the potential applications of pharmacogenomics to RA management by identifying polymorphisms associated with variation in treatment response or toxicity. The use of genetic variants to guide treatment strategy has the potential to not only reduce National Health Service costs, but also drastically improve patient experience and quality of life.
引用
- Dedmon LE. The genetics of rheumatoid arthritis. Rheumatology (Oxford). 2020. PMID: 32638005. doi:10.1093/rheumatology/keaa232
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。